Certara sells biosimulation software, regulatory writing tools, and consulting services that help drug developers and regulators make decisions. CERT reports earnings on Thu, Nov 5, 2026. Analyst consensus is Hold, based on the latest ratings from 3 firms (1 buy, 2 hold, 0 sell). In the past 30 days there were 1 dark pool print.
Prices, price targets and earnings estimates for CERT are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CERT is in one of them and how their past CERT trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Certara
Certara is based in Radnor, Pennsylvania, and provides biosimulation software, regulatory science tools, and consulting services for drug development. Its products include the Simcyp Simulator, which predicts how drugs behave in the body, and the Phoenix software for analyzing pharmacokinetic data. The company also offers CoAuthor software and related services to help draft regulatory submissions. Its customers include biopharmaceutical and biotech companies, academic institutions, and drug regulatory agencies.
